S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics, a subsidiary of Biocon Limited, to ‘BB+’ from ‘BB’. The rating agency has also maintained a stable outlook for the company. This upgrade is a testament to Biocon Biologics’ strong business profile, driven by its robust product portfolio, expanding global presence, and significant investments in research and development.<\/p>\n
The ‘BB+’ rating reflects Biocon Biologics’ established position in the biosimilars market, with a diverse portfolio of products across diabetes, oncology, and immunology. The company’s commitment to innovation and quality has enabled it to build a strong reputation in the industry. S&P Global Ratings noted that Biocon Biologics’ revenue growth is expected to remain robust, driven by the increasing demand for biosimilars globally.<\/p>\n
The rating agency also highlighted the company’s improving profitability, driven by better operating efficiencies and a favorable product mix. Biocon Biologics’ EBITDA margin is expected to remain stable, supported by its ability to manage costs and maintain pricing power. The company’s debt-to-EBITDA ratio is expected to remain moderate, providing it with the flexibility to pursue growth opportunities.<\/p>\n
The stable outlook reflects S&P Global Ratings’ expectation that Biocon Biologics will maintain its strong business profile, driven by its established product portfolio and expanding global presence. The company’s significant investments in research and development are expected to yield new product launches, further enhancing its competitive position.<\/p>\n
The upgrade is a significant milestone for Biocon Biologics, as it reflects the company’s ability to execute its strategy and deliver strong financial performance. The ‘BB+’ rating will provide the company with better access to capital markets, enabling it to pursue its growth plans and expand its global footprint. Biocon Biologics’ strong ratings will also enhance its credibility with customers, partners, and investors, further solidifying its position as a leading player in the biosimilars market.<\/p>\n
Overall, the rating upgrade by S&P Global Ratings is a testament to Biocon Biologics’ strong fundamentals and growth prospects. The company’s commitment to innovation, quality, and customer satisfaction has enabled it to establish a strong position in the industry, and the ‘BB+’ rating reflects its ability to maintain this position and pursue new opportunities for growth.<\/p>\n","protected":false},"excerpt":{"rendered":"
S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics, a subsidiary of Biocon Limited, to ‘BB+’ from ‘BB’. The rating agency has also maintained a stable outlook for the company. This upgrade is a testament to Biocon Biologics’ strong business profile, driven by its robust product portfolio, expanding global presence, and […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14,2],"tags":[],"class_list":["post-89877","post","type-post","status-publish","format-standard","hentry","category-biocon","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89764,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/07\/biocon-biologics-enhances-its-cancer-treatment-offerings-with-the-introduction-of-three-key-biosimilar-products\/","url_meta":{"origin":89877,"position":0},"title":"Biocon Biologics enhances its cancer treatment offerings with the introduction of three key biosimilar products.","author":"Team Small News","date":"January 7, 2026","format":false,"excerpt":"Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The new additions include biosimilar versions of Trastuzumab\/Hyaluronidase, Nivolumab, and Pembrolizumab, which are used to treat various types of cancer. With these new additions, Biocon\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89824,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/19\/biocon-expects-robust-q3-performance-fueled-by-biosimilar-growth\/","url_meta":{"origin":89877,"position":1},"title":"Biocon Expects Robust Q3 Performance Fueled by Biosimilar Growth","author":"Team Small News","date":"January 19, 2026","format":false,"excerpt":"Biocon, a leading biopharmaceutical company, is expected to have a strong third quarter in the fiscal year 2026 (Q3FY26). The company's biosimilars segment is anticipated to drive this growth, with key products such as bStelara playing a significant role. Analysts predict substantial revenue growth, driven by the increasing adoption of\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89747,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/tragedy-strikes-in-bengaluru-as-26-year-old-biocon-staff-member-takes-fatal-leap-from-5th-floor-of-office-building\/","url_meta":{"origin":89877,"position":2},"title":"Tragedy strikes in Bengaluru as 26-year-old Biocon staff member takes fatal leap from 5th floor of office building.","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"A 26-year-old employee of Biocon, a biopharmaceutical company, jumped to his death from the 5th floor of the company's office building in Bengaluru, India. The incident occurred on a recent day, and the police are currently investigating the circumstances surrounding the death. According to reports, the employee, whose identity has\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89794,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/13\/dr-reddys-laboratories-has-been-issued-a-pre-approval-inspection-letter-from-the-usfda-for-its-biologics-facility-located-in-hyderabad\/","url_meta":{"origin":89877,"position":3},"title":"Dr. Reddy’s Laboratories has been issued a pre-approval inspection letter from the USFDA for its biologics facility located in Hyderabad.","author":"Team Small News","date":"January 13, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has received a Pre-Approval Inspection (PAI) letter from the US Food and Drug Administration (USFDA) for its biologics facility located in Hyderabad, India. This letter indicates that the USFDA has completed its inspection of the facility and has found it to be compliant with the required standards.\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89898,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/02\/03\/glenmark-pharmaceuticals-sets-sights-on-fy28-for-debut-of-oncology-drugs-and-expansion-of-profit-margins-reports-etpharma\/","url_meta":{"origin":89877,"position":4},"title":"Glenmark Pharmaceuticals sets sights on FY28 for debut of oncology drugs and expansion of profit margins, reports ETPharma.","author":"Team Small News","date":"February 3, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89870,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/27\/lupin-achieves-top-esg-rating-from-cdp-for-its-efforts-in-addressing-climate-change-and-water-security\/","url_meta":{"origin":89877,"position":5},"title":"Lupin achieves top ESG rating from CDP for its efforts in addressing climate change and water security.","author":"Team Small News","date":"January 27, 2026","format":false,"excerpt":"Lupin, a global pharmaceutical leader, has been recognized for its exceptional sustainability efforts, receiving the highest \"A\" leadership rating from the Climate Disclosure Project (CDP) for both Climate Change and Water Security. This prestigious recognition solidifies Lupin's position among the world's most sustainable and transparent companies. The double \"A\" rating\u2026","rel":"","context":"In "Lupin"","block_context":{"text":"Lupin","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/lupin\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89877"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89877\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}